The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola.
A planned sample of 26 participants – who must be assessed as healthy and aged 18 to 55 – will all receive one dose of the ChAdOx1 biEBOV vaccine at the University. Following vaccination, participants will be monitored through several visits over a six-month period, with results expected in the second quarter of 2022.
